We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Widely Available Blood Tests Enhance Diagnostic Sensitivity of Fungal Infections

By LabMedica International staff writers
Posted on 18 Sep 2023
Print article
Image: Two widely available serum marker blood tests improve diagnostic sensitivity of invasive fungal infections (Photo courtesy of 123RF)
Image: Two widely available serum marker blood tests improve diagnostic sensitivity of invasive fungal infections (Photo courtesy of 123RF)

Invasive fungal infections (IFIs) are on the rise and are especially dangerous for immunocompromised individuals, causing high morbidity and mortality. Diagnosing these infections in a timely and accurate manner is tough, largely because the current method—using punch biopsies for tissue culture and histology—yields unreliable results with only about a 10% match rate. Now, a new study has found that the use of newer tests can improve the diagnosis of this time-sensitive condition.

In the study, researchers at Thomas Jefferson University (Philadelphia, PA, USA) found that two commonly available serum marker blood tests, galactomannan and 1,2-beta-D-glucan, were capable of improving diagnostic sensitivity in IFI cases. The first test, serum galactomannan (GM), is a polysaccharide antigen present specifically in the cell walls of Aspergillus fungi. According to the study, this test is effective for diagnosing invasive aspergillosis, showing a sensitivity range of 63% to 78% and a specificity range of 85% to 93%. A unique advantage of GM is its ability to distinguish between aspergillosis and mucormycosis. However, the researchers have cautioned that the test's sensitivity may decrease if the patient is already undergoing systemic antifungal therapy, particularly mold-active agents.

The second test, 1,2-beta-D-glucan (BDG), is a component found in the cell walls of a range of fungi, including Candida, Aspergillus, and Pneumocystis jirovecii. As many fungi contain BDG, the test is more useful for broadly identifying the presence of fungal etiology rather than specific causative agents. Past meta-analyses have shown that BDG can distinguish between probable and unlikely IFIs with a sensitivity of 77% and a specificity of 85%. However, dermatologists need to be aware that this test can yield false positives, as it does not differentiate between various fungal species. Hence, it may not be suitable for patients with a low likelihood of having an IFI, suggests the study. The researchers have recommended that dermatologists use these blood tests alongside traditional histopathology and cultures to enhance diagnostic sensitivity.

“A double negative GM and BDG can lower the probability of an IFI and encourage providers to seek alternative diagnoses,” stated the researchers.

Related Links:
Thomas Jefferson University

New
Platinum Supplier
Automatic Nucleic Acid Workstation
Pana9600X
Gold Supplier
Automated Staining Unit
RAL Stainer
New
C3GR-E Test
CHROMagar C3GR
New
cTnI Test
OnSite Troponin I Combo Rapid Test

Print article
GLOBETECH PUBLISHING LLC

Channels

Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: A CRISPR technology-based diagnostic test detects MPXV in clinical samples with acute precision (Photo courtesy of 123RF)

Powerful Diagnostic Tool Accurately Detects Monkeypox Virus Faster Than Any Method

At present, testing for the monkeypox virus (MPXV) is done mainly in centralized labs, and it can take days to get results due to location and logistical issues. Now, researchers have leveraged cutting-edge... Read more

Hematology

view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more

Immunology

view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more

Microbiology

view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.